NRM‑823

N/A

Report date: 2025/09/23 20:00:05

Base Information

Drug NameNRM‑823
Drug Alias NameNRM‑823
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsEsophageal adenocarcinomaUterine Cervical NeoplasmsEndometrial Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNormunity Inc
China Registration ClassN/A

Develop Information

Active CompaniesNormunity AccelCo Inc
Inactive CompaniesNormunity Inc
Active IndicationsEsophageal adenocarcinomaUterine Cervical NeoplasmsEndometrial Neoplasms +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A